Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuemei Luo

Showing results (151-160 of 185) with videos related to

Pageof 19
Sort By:
Frontiers in Pharmacology|May 27, 2024
Population pharmacokinetics, dosing optimization and clinical outcomes of biapenem in patients with sepsisDayu Chen, Xuanyu Wu, Haixia Zhang, et al.
Plos One|January 27, 2018
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approachXiaoyan Li, Allison Keshishian, Melissa Hamilton, et al.
Journal of Environmental Management|December 26, 2025
STAR: Soil texture analysis recognizer integrating domain-adaptive transfer learning with NIR spectroscopyYuchen Luo, Zeyuan Zhang, Siyu Liu, et al.
Thrombosis and Haemostasis|March 17, 2017
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patientsXiaoyan Shawn Li, Steve Deitelzweig, Allison Keshishian, et al.
The American Journal of Cardiology|March 5, 2021
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery DiseaseRenato D Lopes, Laine Thomas, Manuela Di Fusco, et al.
Thrombosis and Haemostasis|January 28, 2020
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical PracticeDerek Weycker, Xiaoyan Li, Gail DeVecchis Wygant, et al.
Thrombosis and Haemostasis|October 26, 2018
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical PracticeDerek Weycker, Xiaoyan Li, Gail DeVecchis Wygant, et al.
Plos One|February 20, 2014
Use of Sequenom sample ID Plus® SNP genotyping in identification of FFPE tumor samplesJessica K Miller, Nicholas Buchner, Lee Timms, et al.
Stroke|December 21, 2018
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation PatientsGregory Y H Lip, Allison Keshishian, Xiaoyan Li, et al.
Journal of Thrombosis and Thrombolysis|April 30, 2022
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort studySteve Deitelzweig, Xuemei Luo, Jennifer L Nguyen, et al.
Pageof 19

Showing results (151-160 of 185) with videos related to

Sort By:
Pageof 19
Frontiers in Pharmacology|May 27, 2024
Population pharmacokinetics, dosing optimization and clinical outcomes of biapenem in patients with sepsisDayu Chen, Xuanyu Wu, Haixia Zhang, et al.
Plos One|January 27, 2018
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approachXiaoyan Li, Allison Keshishian, Melissa Hamilton, et al.
Journal of Environmental Management|December 26, 2025
STAR: Soil texture analysis recognizer integrating domain-adaptive transfer learning with NIR spectroscopyYuchen Luo, Zeyuan Zhang, Siyu Liu, et al.
Thrombosis and Haemostasis|March 17, 2017
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patientsXiaoyan Shawn Li, Steve Deitelzweig, Allison Keshishian, et al.
The American Journal of Cardiology|March 5, 2021
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery DiseaseRenato D Lopes, Laine Thomas, Manuela Di Fusco, et al.
Thrombosis and Haemostasis|January 28, 2020
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical PracticeDerek Weycker, Xiaoyan Li, Gail DeVecchis Wygant, et al.
Thrombosis and Haemostasis|October 26, 2018
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical PracticeDerek Weycker, Xiaoyan Li, Gail DeVecchis Wygant, et al.
Plos One|February 20, 2014
Use of Sequenom sample ID Plus® SNP genotyping in identification of FFPE tumor samplesJessica K Miller, Nicholas Buchner, Lee Timms, et al.
Stroke|December 21, 2018
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation PatientsGregory Y H Lip, Allison Keshishian, Xiaoyan Li, et al.
Journal of Thrombosis and Thrombolysis|April 30, 2022
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort studySteve Deitelzweig, Xuemei Luo, Jennifer L Nguyen, et al.
Pageof 19